切换至 "中华医学电子期刊资源库"

中华普外科手术学杂志(电子版) ›› 2023, Vol. 17 ›› Issue (02) : 157 -161. doi: 10.3877/cma.j.issn.1674-3946.2023.02.012

论著

肝癌中线粒体膜蛋白ATAD3A表达与临床病理特征及预后的关系
李晖1, 范志勇1, 耿西林1, 常虎林1,(), 吴武军1, 张煜1   
  1. 1. 710068 西安,陕西省人民医院肝胆外科
  • 收稿日期:2022-06-07 出版日期:2023-04-26
  • 通信作者: 常虎林

Relationship between mitochondrial membrane protein ATAD3A expression and clinicopathological features and prognosis in hepatocellular carcinoma

Hui Li1, Zhiyong Fan1, Xilin Geng1, Hulin Chang1,(), Wujun Wu1, Yu Zhang1   

  1. 1. Liver and Gallbladder Surgery, Shaanxi Provincial People’s Hospital, Xi’an Shaanxi Province 710068, China
  • Received:2022-06-07 Published:2023-04-26
  • Corresponding author: Hulin Chang
  • Supported by:
    Natural Science Basic Research Program of Shaanxi Province(2020JQ-948); Science and Technology Research and Development Program of Shaanxi Province(2014K11-03-03-11)
引用本文:

李晖, 范志勇, 耿西林, 常虎林, 吴武军, 张煜. 肝癌中线粒体膜蛋白ATAD3A表达与临床病理特征及预后的关系[J/OL]. 中华普外科手术学杂志(电子版), 2023, 17(02): 157-161.

Hui Li, Zhiyong Fan, Xilin Geng, Hulin Chang, Wujun Wu, Yu Zhang. Relationship between mitochondrial membrane protein ATAD3A expression and clinicopathological features and prognosis in hepatocellular carcinoma[J/OL]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(02): 157-161.

目的

检测肝癌组织中线粒体膜蛋白ATAD3A表达情况,探究其与肝癌临床病理特征及预后的关系。

方法

选取2016年7月至2018年3月行手术治疗的85例肝癌患者癌组织及其对应癌旁组织(距癌灶边缘3~5 cm)标本进行研究。采用免疫组织化学染色法和qRT-PCR检测肝癌组织及癌旁组织中ATAD3A蛋白及mRNA表达情况。采用SPSS 25.0统计软件进行数据分析,计量资料以(

xˉ
±s)表示,计数资料用[n(%)]表示,ATAD3A表达与临床病理特征的相关性采用χ2t检验,Kaplan-Meier生存曲线分析预后,COX回归分析预后生存危险因素。P<0.05认为差异有统计学意义。

结果

肝癌组织中ATAD3A蛋白阳性表达率为28.2%(24/85),mRNA相对表达水平为(2.6±0.5),明显低于癌旁正常组织的76.5%(65/85)和(4.8±0.9),差异有统计学意义(χ2=39.641,t=19.701,P<0.001)。ATAD3A蛋白及mRNA表达与肝癌肿瘤直径、分化程度、TNM分期及脉管癌栓等病理特征关系密切,差异有统计学意义(χ2=39.641,P<0.05)。ATAD3A阳性组患者术后5年累积总生存率为58.3%,阴性组患者术后5年累积总生存率为41.0%,差异有统计学意义(Log-Rank χ2=4.317,P=0.038)。肿瘤直径、分化程度、TNM分期、伴脉管癌栓及ATAD3A阴性表达是影响肝癌患者预后不良的独立危险因素(P<0.05)。

结论

肝癌组织中ATAD3A显著阴性/低表达,与肿瘤直径、分化程度、TNM分期、脉管癌栓等病理特征关系密切,可能参与病情进展;ATAD3A阴性表达是影响肝癌患者预后不良的独立危险因素,可将其作为判断预后的分子标志物。

Objective

The expression of mitochondrial membrane protein ATAD3A in liver cancer tissues was detected to explore its relationship with the clinicopathologic features and prognosis of liver cancer.

Methods

Cancer tissues and corresponding paracancer tissues(3~5 cm away from the edge of cancer foci)of 85 patients with liver cancer who underwent surgical treatment from July 2016 to March 2018 were selected for study. Immunohistochemical staining and qRT-PCR were used to detect the expression of ATAD3A protein and mRNA in liver cancer tissues and adjacent tissues. SPSS 25.0 statistical software was used for data analysis,the measurement data were represented by(

xˉ
±s),and the count data were represented by[n(%)]. The correlation between ATAD3A expression and clinicopathological features was analyzed by χ2 or t test,Kaplan-Meier survival curve was used to analyze the prognosis,and Cox regression was used to analyze the prognosis and survival risk factors. P<0.05 was considered statistically significant.

Results

The positive expression rate of ATAD3A protein in liver cancer tissues was 28.2%(24/85),and the relative expression level of mRNA was(2.6±0.5),which was significantly lower than that of adjacent normal tissues(76.5%(65/85)and(4.8±0.9),and the difference was statistically significant(χ2=39.641,t=19.701,P<0.001). The expression of ATAD3A protein and mRNA were closely related to tumor diameter,differentiation degree,TNM stage and vascular cancer thrombus,and the differences were statistically significant(χ2=39.641,P<0.05). The 5-year cumulative overall survival rate was 58.3% in the ATAD3A positive group and 41.0% in the negative group,with statistically significant differences(Log-Rank χ2=4.317,P=0.038). Tumor diameter,degree of differentiation,TNM stage,vascular cancer thrombin and ATAD3A negative expression were independent risk factors for poor prognosis in patients with HCC(P<0.05).

Conclusion

ATAD3A expression was significantly negative/low in liver cancer tissues,which was closely related to tumor diameter,differentiation degree,TNM stage,vascular cancer thrombus and other pathological characteristics,and may be involved in disease progression. Negative expression of ATAD3A is an independent risk factor for poor prognosis in patients with liver cancer and can be used as a molecular marker for prognosis.

图1 肝癌组织中ATAD3A蛋白免疫组织化学染色图(×400)注:a=阴性(-);b=弱阳性(+);c=强阳性(+++)。
表1 肝癌组织及癌旁组织中ATAD3A蛋白及mRNA表达[(
xˉ
±s),例]
表2 85例ATAD3A表达与肝癌临床病理特征的相关性分析[(
xˉ
±s),例]
图2 ATAD3A表达与肝癌患者预后的K-M生存曲线
表3 COX回归分析肝癌患者预后因素
[1]
Chidambaranathan-Reghupaty SPaul BFDevanand S. Hepatocellular carcinoma(HCC):Epidemiology,etiology and molecular classification[J]. Adv Cancer Res2021149:1-61.
[2]
Siu EHChan AWChong CC,et al. Treatment of advanced hepatocellular carcinoma:Immunotherapy from checkpoint blockade to potential of cellular treatment[J]. Transl Gastroenterol Hepatol20183:89.
[3]
魏鑫,刘斌,王飞通. 三种不同肝切除术式治疗原发性肝癌的临床比较[J/CD]. 中华普外科手术学杂志(电子版)201711(05):383-386.
[4]
Dorison NGaignard PBayot A,et al. Mitochondrial dysfunction caused by novel ATAD3A mutations[J]. Mol Genet Metab2020131(1-2):107-113.
[5]
Teng Y. Mitochondrial Protein ATAD3A and Cancer[J]. International Journal of Molecular Sciences202021(21):1-14.
[6]
Teng YLang LShay C. ATAD3A on the Path to Cancer[J]. Adv Exp Med Biol20191134:259-269.
[7]
冯亚星,周龙甫,王一涵,等. 过表达ATAD3A诱导大鼠正常肝干细胞发生上皮-间质转化[J]. 第三军医大学学报201941(24):2417-2424.
[8]
丁建龙,刘晓晨,段建峰,等. 两种肝切除方式治疗Ⅲ/Ⅳ型肝门部胆管癌的疗效及安全性比较[J/CD]. 中华普外科手术学杂志(电子版)202115(06):686-689.
[9]
Wang CYoule R. Cell biology:Form follows function for mitochondria[J]. Nature2016530(7590):288-289.
[10]
Yusoff AAMAbdullah WSWKhair SZNM,et al. A comprehensive overview of mitochondrial DNA 4977-bp deletion in cancer studies[J]. Oncol Rev201913(1):409.
[11]
Peralta SGoffart SWilliams SL,et al. ATAD3 controls mitochondrial cristae structure,influencing mtDNA replication and cholesterol levels in muscle[J]. J Cell Sci2018131(13):jcs217075.
[12]
Cheng GHardy MTopchyan P,et al. Potent inhibition of tumour cell proliferation and immunoregulatory function by mitochondria-targeted atovaquone[J]. Sci Rep202010(1):17872.
[13]
Finsterer JAliyev R. ATAD3A variants manifest multisystematically in the brain,nerves,eyes,heart,liver,and skin[J]. Mol Genet Metab Rep202022:100569.
[14]
Huang KCYChiang SFYang PC,et al. ATAD3A stabilizes GRP78 to suppress ER stress for acquired chemoresistance in colorectal cancer[J]. J Cell Physiol2021236(9):6481-6495.
[15]
杨世荣,白翔宇,吴迪,等. ATAD3A在结直肠癌组织中的表达及其对细胞生长的影响[J].现代生物医学进展202020(06):1022-1037,1074.
[16]
罗茂,罗卓夫,毕建军,等. 沉默ATAD3A对黑素瘤A375细胞增殖,侵袭和迁移的影响及机制研究[J]. 中华皮肤科杂志202053(07):539-545.
[17]
Daniel PHalada PJelínek M,et al. Differentially Expressed Mitochondrial Proteins in Human MCF7 Breast Cancer Cells Resistant to Paclitaxel[J]. Int J Mol Sci201920(12):2986.
[18]
Terrasi ABertolini IMartelli C,et al. Specific V-ATPase expression sub-classifies IDHwt lower-grade gliomas and impacts glioma growth in vivo[J]. Ebiomedicine201941:214-224.
[19]
Han HJHuang QYHuang LJ,et al. Prognostic value of ATPase family,AAA+ domain containing 2 expression in human cancers:A systematic review and meta-analysis[J]. Medicine(Baltimore)201998(39):e17180.
[20]
任婧,班超,张露丹,等. 肝癌患者术后生存的影响因素分析[J]. 癌症进展201917(23):2819-2821,2842.
[1] 许杰, 李亚俊, 韩军伟. 两种入路下腹腔镜根治性全胃切除术治疗超重胃癌的效果比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 19-22.
[2] 李华志, 曹广, 刘殿刚, 张雅静. 不同入路下行肝切除术治疗原发性肝细胞癌的临床对比[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 52-55.
[3] 常小伟, 蔡瑜, 赵志勇, 张伟. 高强度聚焦超声消融术联合肝动脉化疗栓塞术治疗原发性肝细胞癌的效果及安全性分析[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 56-59.
[4] 高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[5] 李代勤, 刘佩杰. 动态增强磁共振评估中晚期低位直肠癌同步放化疗后疗效及预后的价值[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 100-103.
[6] 屈翔宇, 张懿刚, 李浩令, 邱天, 谈燚. USP24及其共表达肿瘤代谢基因在肝细胞癌中的诊断和预后预测作用[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 659-662.
[7] 顾雯, 凌守鑫, 唐海利, 甘雪梅. 两种不同手术入路在甲状腺乳头状癌患者开放性根治性术中的应用比较[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 687-690.
[8] 付成旺, 杨大刚, 王榕, 李福堂. 营养与炎症指标在可切除胰腺癌中的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 704-708.
[9] 韩加刚, 王振军. 梗阻性左半结肠癌的治疗策略[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 450-458.
[10] 刘郁, 段绍斌, 丁志翔, 史志涛. miR-34a-5p 在结肠癌患者的表达及其与临床特征及预后的相关性研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 485-490.
[11] 陈倩倩, 袁晨, 刘基, 尹婷婷. 多层螺旋CT 参数、癌胚抗原、错配修复基因及病理指标对结直肠癌预后的影响[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 507-511.
[12] 曾明芬, 王艳. 急性胰腺炎合并脂肪肝患者CT 与彩色多普勒超声诊断参数与其病情和预后的关联性研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 531-535.
[13] 沈炎, 张俊峰, 唐春芳. 预后营养指数结合血清降钙素原、胱抑素C及视黄醇结合蛋白对急性胰腺炎并发急性肾损伤的预测价值[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 536-540.
[14] 王景明, 王磊, 许小多, 邢文强, 张兆岩, 黄伟敏. 腰椎椎旁肌的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 846-852.
[15] 郭曌蓉, 王歆光, 刘毅强, 何英剑, 王立泽, 杨飏, 汪星, 曹威, 谷重山, 范铁, 李金锋, 范照青. 不同亚型乳腺叶状肿瘤的临床病理特征及预后危险因素分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(06): 524-532.
阅读次数
全文


摘要